ClinicalTrials.gg
Status unknownNCT01947062Updated Sep 20, 2013

Metronomic Cyclophosphamide in Combination With Standard Chemotherapy for Squamous Cell Lung Carcinoma

A Phase 3 interventional study of Intravenous Cisplatin & etoposide and Intravenous Cisplatin & etoposide along with oral cyclophosphamide in Lung Cancer, Squamous Cell Carcinoma of the Lung and Locally Advanced and Metastatic Squamous Cell Carcinoma of the Lung, sponsored by Swami Rama Cancer Hospital and Research Institute. Status unknown at 1 site in India. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2013-09-20.

Sponsored by Swami Rama Cancer Hospital and Research Institute · Phase 3, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Sep 2013), so the status shown — last known as Not yet recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 115 studies testing cisplatin in Lung Neoplasms — 5 open to participants now, 9 under way, 2 of them phase 3. Cisplatin · Lung Neoplasms.

Planned enrollment
39th of 99
60 · median 47
Started
2013
with 1 other
Phase 3
22 of 115
none open now
Registered
93rd of 115
by date

Among the 115 studies testing cisplatin in Lung Neoplasms, this one is the 39th largest by planned enrollment of the 99 interventional ones that give a count, is one of 2 that started in 2013, is one of 22 in phase 3, and was the 93rd registered.

Lung Neoplasms

5,424 studies on the registry are indexed under Lung Neoplasms; 1,345 are open to participants now.

Browse Lung Neoplasms studies →

Open to participants now

5 of the 115 studies testing cisplatin in Lung Neoplasms are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About cisplatin

Cisplatin: first FDA approval 1978 (PLATINOL-AQ). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 995 Lung Neoplasms studies recruiting now, 682 (69%) set no upper age limit and 142 (14%) stop at 75 or younger; 45 take children under 18; 142 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 115 studies testing cisplatin in Lung Neoplasms, or all of them as a file.
02

Study summary

Treatment of locally advanced and metastatic squamous cell carcinoma of the lung involves the use of chemotherapy as the therapeutic mainstay. Platinum-etoposide regimens (such as cisplatin-etoposide) are the most commonly used chemotherapeutic regimen, which is delivered intravenously in the standard three-weekly intervals.

Recent interest in oral metronomic chemotherapy has arisen, especially due to its beneficial effects in delaying disease progression among heavily pre-treated patients with various malignancies.

This study attempts to combine the use of metronomic chemotherapy concurrently during standard intravenous chemotherapy.

Read the detailed description

Adenocarinoma and squamous cell carinoma are the two major types of non-small cell lung carcinoma. While patients with adenocarcinoma of the lung have the feasibility of treatment with tyrosine kinase inhibitors, the patients with squamous cell carcinoma can only be treated with standard chemotherapy due to the ineffectiveness of tyrosine kinase inhibitors. Thus, the current standard is to treat patients of squamous cell lung cancers with standard intravenous chemotherapy, which is mostly delivered once in three weeks.

Metronomic chemotherapy, meaning the delivery of low doses of chemotherapy, often by an oral approach, on a daily basis so as to maintain a low but definite level of the chemotherapy has received great interest in recent times due to its beneficial effects in terms of extending progression free survival among patients of various malignancies, even after failure with previous conventional therapies. Metronomic chemotherapy is proposed to be active by alternate mechanisms, such as the predominant anti-angiogenic effect, in contrast to the cytotoxic and genotoxic effects of standard chemotherapy.

Metronomic chemotherapy with oral cyclophosphamide has been shown to extend progression free survival when used as a single agent in various malignancies. Given the fact that progression after varying time spans is a rule (rather than the exception) among patients of squamous cell lung cancer being treated with conventional chemotherapy, we have intended to combine the use of oral metronomic chemotherapy given concurrently with standard intravenous cisplatin-etoposide based chemotherapy. We intend to observe a prolongation of progression free survival.

03

Conditions studied

  • Lung Cancer
  • Squamous Cell Carcinoma of the Lung
  • Locally Advanced and Metastatic Squamous Cell Carcinoma of the Lung

Browse trials for

Keywords

  • NSCLC
  • Metronomic chemotherapy
  • Metronomic cyclophosphamide
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Histopathologically proven squamous cell carcinoma of the lung
  • Surgically unresectable or disease

Exclusion criteria

Exclusion Criteria:

  • Severe life limiting diabetes, hypertension or cardiac co-morbidities
  • Co-existing tuberculosis
  • at presentation
  • Non-consenting patients
  • Previously treated with any regimen of chemotherapy for existing or previous
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
60 participants (estimated)

Study arms

  • Active comparator
    Standard intravenous chemotherapy

    Patients will receive standard intravenous chemotherapy based on cisplatin and etoposide.

    Drug: Intravenous Cisplatin & etoposide

  • Experimental
    Intravenous with metronomic chemotherapy

    Patients will receive both intravenous (cisplatin and etoposide based) and metronomic chemotherapy (with oral cyclophosphamide).

    Drug: Intravenous Cisplatin & etoposide along with oral cyclophosphamide

Interventions

  • DrugIntravenous Cisplatin & etoposide

    Drug pages: Cisplatin · Etoposide

    Patients will receive standard intravenous cisplatin and etoposide based chemotherapy, for a total of six cycles, delivered at three-weekly intervals. In each cycle, the dose of cisplatin will be at 50mg/m2 on days 1 \& 2. The dose of etoposide will be 100mg/m2 on days 1, 2 \& 3.

    Also known as: Control arm, Standard intravenous chemotherapy

  • DrugIntravenous Cisplatin & etoposide along with oral cyclophosphamide

    Drug pages: Cisplatin · Etoposide · Cyclophosphamide

    Patients will be treated with oral cyclophosphamide at a daily dose of 50mg. Patients will also receive standard intravenous cisplatin and etoposide based chemotherapy, for a total of six cycles, delivered at three-weekly intervals. In each cycle, the dose of cisplatin will be at 50mg/m2 on days 1 \& 2. The dose of etoposide will be 100mg/m2 on days 1, 2 \& 3.

    Also known as: Experimental arm, Intravenous with metronomic chemotherapy

06

What researchers measure

Primary outcomes

  1. Progression free survival

    Time frame: 12 months on average

Secondary outcomes

  1. Response rate

    Time frame: 12 months on average

07

Study locations

1 site
  • Swami Rama Cancer Hospital & Research Institute
    Haldwani, Nainital, Uttarakhand 263139, India
    • Swaroop Revannasiddaiah, MD · Contactswarooptheone@gmail.com · 91
    • Swaroop Revannasiddaiah, MD · Principal investigator
    • Kailash C Pandey, MD · Sub investigator
    • Sridhar P Susheela, MD · Sub investigator
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2013, a primary completion of Jun 2014 and a completion of Oct 2014. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 10, 2013
First posted
Sep 20, 2013
Start
Oct 2013
Primary completionEst.
Jun 2014
CompletionEst.
Oct 2014
Last update
Sep 20, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 20, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01947062
Lead sponsor
Swami Rama Cancer Hospital and Research Institute
Responsible party
Swaroop Revannasiddaiah (Assistant Professor, Radiotherapy & Clinical Oncology, Swami Rama Cancer Hospital and Research Institute) — Principal investigator
First posted
Sep 20, 2013
Start date
Oct 2013
Primary completion
Jun 2014 (estimated)
Completion
Oct 2014 (estimated)
Last update
Sep 20, 2013

Study contacts

Swaroop Revannasiddaiah, MD
Contact
swarooptheone@gmail.com
+91 ext. 8971862565
Kailash C Pandey, MD
Contact
drkcp89@gmail.com
+91 ext. 9634652758

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Sep 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Cisplatin · Etoposide · Cyclophosphamide

Start the discussion